课题基金 / 基金详情

项目摘要

项目成果

Ahmet Hoke的其他基金

相似基金

相关文献

中文摘要
翻译
项目摘要 糖尿病周围神经病变(DPN)是糖尿病患者周围神经病变的最常见原因。 发达国家,并导致显著的发病率和相关的医疗费用。它影响了30%的 降低了患者的生活质量。DPN的主要缺陷是导致 患者的症状是末梢轴突的远端变性,也称为回退性轴突病。 虽然存在一些对症治疗,但这些只是部分有效,目前还没有 除了严格的糖尿病治疗外, 控制即使在糖尿病控制良好的患者中,DPN也可能进展,强调了DPN的复杂生物学特性。 伴有代谢综合征的糖尿病患者的轴突变性 虽然糖尿病中轴突退化的潜在机制可能是 复杂并涉及多个受损的分子通路,轴突的最终降解, 导致轴突变性的组分包括与编程轴突共享的关键分子参与者, 退化这些酶包括NAD+合成酶NMNAT 2和NAD+降解酶Sarm 1。 Sarm 1的激活是轴突变性所必需的,但这种激活是如何调节的仍在研究中。 调查几年前,我们采取了一种不同的方法来开发治疗靶点, 周围神经病变中的轴突变性。我们没有针对特定的途径,而是从一个 表型药物筛选,以防止轴突变性,并确定SF 3B 2,一个组成部分, 剪接体复合物在预防化疗药物引起的轴突变性中起关键作用。 我们的初步研究表明SF 3B 2是Sarm 1激活的上游,并提供了一种替代治疗方法。 靶点可能避免Sarm 1抑制的潜在脱靶副作用。 在本申请中要测试的首要假设是,在以下方面起关键作用的分子: 程序性轴突变性在糖尿病周围神经病变的发生和发展中起重要作用。 神经病变,用新药靶向它们可能提供新的治疗机会。我们将 通过i)检查感觉神经元特异性遗传缺失Sarm 1和SF 3B 2的影响来检验这些假设 在2型糖尿病的高脂肪饮食(HFD)模型中对周围神经病变的发展的影响; ii)鉴定 iii)测试EQ-6在DPN的HFD模型中的功效。
英文摘要
Project Summary Diabetic peripheral neuropathy (DPN) is the most common cause of peripheral neuropathy in the developed world and cause significant morbidity with associated healthcare expenses. It affects up to 30% of all diabetic patients and reduces the quality of life of patients. The primary defect in DPN that results in patient symptoms is the distal degeneration of peripheral axons, also known as dying-back axonopathy. Although some symptomatic therapies exist, these are only partially effective and currently there is no treatment that halts or reverses the axon degeneration or disease progression apart from strict diabetic control. DPN may progress even in patients with good diabetic control, emphasizing the complex biology of axon degeneration in diabetic patients with associated metabolic syndrome. Although the underlying mechanisms of dying-back axon degeneration in diabetes is likely to be complex and involve multiple impaired molecular pathways, the eventual degradation of axonal components leading to axonal degeneration includes key molecular players shared with programmed axon degeneration. These include NAD+ synthesizing enzyme, NMNAT2 and NAD+ degrading enzyme, Sarm1. Activation of Sarm1 is required for axonal degeneration but how this activation is regulated is still under investigation. Several years ago, we took a different approach to developing therapeutic targets to prevent axonal degeneration in peripheral neuropathies. Instead of targeting a specific pathway, we started with a phenotypic drug screen to prevent axon degeneration and identified SF3B2, a component of the spliceosome complex as playing a key role in preventing axon degeneration caused by chemotherapy drugs. Our preliminary studies indicate SF3B2 is upstream of Sarm1 activation and offer an alternative therapeutic target that may spare potential off-target side effects of Sarm1 inhibition. The overarching hypothesis to be tested in this application is that molecules that play a key role in programmed axon degeneration are important in development and progression of diabetic peripheral neuropathy and that targeting them with a novel drug may offer new therapeutic opportunities. We will test these hypotheses by i) examining the effect sensory neuron specific genetic deletion Sarm1 and SF3B2 on development of peripheral neuropathy in high fat diet (HFD) model of type 2 diabetes; ii) identifying mechanism of action of SF3B2 and iii) testing the efficacy of EQ-6 in the HFD model of DPN.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Macrophage-targeted dendrimer 2-PMPA for the treatment of age-related sarcopenia
  • 批准号:
    10683227
  • 项目类别:
  • 资助金额:
    $51.81万
  • 财政年份:
    2022
  • 负责人:
    Ahmet Hoke
  • 依托单位:
Mechanism of neuroprotection in chemotherapy induced peripheral neuropathy
  • 批准号:
    9765421
  • 项目类别:
  • 资助金额:
    $35.44万
  • 财政年份:
    2015
  • 负责人:
    Ahmet Hoke
  • 依托单位:
Mechanism of neuroprotection in chemotherapy induced peripheral neuropathy
  • 批准号:
    9538270
  • 项目类别:
  • 资助金额:
    $35.44万
  • 财政年份:
    2015
  • 负责人:
    Ahmet Hoke
  • 依托单位:
Mechanism of neuroprotection in chemotherapy induced peripheral neuropathy
  • 批准号:
    9134225
  • 项目类别:
  • 资助金额:
    $35.44万
  • 财政年份:
    2015
  • 负责人:
    Ahmet Hoke
  • 依托单位:
海外基金